BI 2536

Overview

BI 2536 is a dual PLK1 and BRD4 inhibitor with IC 50 s of 0.83 and 25 nM, respectively. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Polo-like Kinase (PLK) | Products > Signaling Pathways > Epigenetic Reader Domain | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-50698
• CAS No.: 755038-02-9
• Molecular Formula: C28H39N7O3
• Molecular Weight: 521.65
• Purity: 99.92%
• Storage: 4°C, protect from light * In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)
• Solubility: ≥ 3.25 mg/mL (6.23 mM); Clear solution
• Availability: In-stock

Source

Original product source